Analysts See $0.20 EPS for Cipher Pharmaceuticals Inc. (CPH) as of May, 10

May 3, 2018 - By Lena Young

On May, 10 WallStreet anticipated Cipher Pharmaceuticals Inc. (TSE:CPH)’s earnings release, Zacks reports. Analysts expect change of 122.22 % or $0.11 from previous year’s $0.09 earnings per share compared to current’s $0.20 earnings per share. This could be $5.34 million profit for T_CPH assuming the current $0.20 earnings per share will become reality. Wall Street now forecasts 5.26 % EPS growth despite Cipher Pharmaceuticals Inc. previous quarter’s EPS of $0.19. CPH is reaching $3.53 during the last trading session, after decreased 0.56%.Currently Cipher Pharmaceuticals Inc. is after 0.00% change in last May 3, 2017. CPH has also 31,000 shares volume. CPH underperformed by 11.55% the S&P 500.

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology firm in South America, Canada, and the United States.The company has $94.33 million market cap. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.21.66 is the P/E ratio. The firm also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Sitavig, a tablet for the treatment of herpes labialis in immunocompetent adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: